Alex Gorsky has left the building. As Novartis' U.S. pharma CEO, Gorsky (photo [1]) had been with the company four years; he's now "pursuing opportunities outside of the company."
Hmm. Just four months ago, Novartis shuffled its management deck [2], naming ex-private equity manager Joe Jiminez as worldwide pharma CEO. Jiminez had been on AstraZeneca's board and an exec at Heinz. And the company is in the midst of a $1.6 billion restructuring that will include 2,500 job cuts [3]. CEO Dan Vasella (photo [4]) has said that he wants to flatten out the company's org chart; he was appalled to discover six layers of management beneath him.
Was Gorsky one of those layers? The company isn't saying; in a message to Pharmalot, Novartis thanked him for his "strong leadership" and wished him well "in his new role," saying that his replacement "will be announced at a later date." Of course, Gorsky may have left of his own accord, and may pop up soon at a competitor. We'll have to watch and see where he lands.
- read the Pharmalot item [5]
Related Articles:
CEO: Novartis plans big restructuring. Report [2]
Lagging sales spur Novartis layoffs. Report [3]
Novartis makes the "Biggest Splash". Report [6]
Links:
[1] http://www.fiercebiotech.com/pages/alex-gorsky
[2] http://www.fiercepharma.com/story/ceo-novartis-plans-big-restructuring/2007-12-11
[3] http://www.fiercepharma.com/story/lagging-sales-spur-novartis-layoffs/2007-10-18
[4] http://www.fiercebiotech.com/pages/novartis-ceo-daniel-vasella
[5] http://www.pharmalot.com/2008/02/novartis-us-pharma-ceo-gorsky-resigns/
[6] http://www.fiercebiotech.com/story/novartis-makes-biggest-splash/2007-10-18